Had a peer-to-peer this morning asking for 15 fraction IMRT with daily IGRT and ended up getting approved for 20 fraction IMRT with daily IGRT. Is this real life??? Dropping knowledge and channeling my inner Jason Beckta

Say hello to your newest board certified radiation oncologist 😎 special thanks to my family and friends for putting up with me over the last decade of medical training.

Getting that CME at #ASCO22

While I prefer the Armageddon approach, this is a close 2nd.

Strong work from the University of Chicago Radiation Oncology team! Stk11m drives dif POF. And those high risk/inoperable may be at higher risk for DM not bc of treatment modality but prob bc of tumor biology.

Wow -- another de-escalation study in HPV+ HNSCC negative. I think many people thought this would do the trick. Clearly, can not de-escalate all comers in HPV+ OPC.

Just tested out #ChatGPT’s ability to write a letter to an insurance company with citations supporting RT for oligomets. It took ~ten seconds 🤯 #radonc

Enterprise Alexandra at ROC airport in Rochester was wonderful - quick, efficient, friendly, welcoming

With Docace911 we present our dogma challenging #RadOnc & #immunotherapy manuscript showing safety & prelim efficacy of partial tumor irradiation with anti-PD1. In contrast w aBscopal, we suggest an aDscopal effect where IO enhances local #radiation. jci.org/articles/view/…

Congratulations Mark Korpics Benjamin Onderdonk Jared Hara (current PGY5!) Ralph Weichselbaum Docace911 Jason Luke, MD, FACP for their analysis of a phase I trial of #SBRT + Pembrolizumab, published in Journal of Clinical Investigation ! #radonc jci.org/articles/view/…

Great time at #ARS2023! Mahalo 🤙

Another great poster at ASCO #ASCO23 showing the results from combinatorial treatment of partial tumor irradiation with pembrolizumab in advanced solid tumor metastasis. Mark Korpics Ralph Weichselbaum University of Chicago Radiation Oncology UChicagoCancerCenter

🎙️Important findings on treatment for #nasopharyngealcarcinoma‼️The Lancet Oncology 📌Ph 3 trial w/240 🇨🇳👥 T1-4N2-3 👥➡️ IMRT + Cis ➡️ random➡️Cis w/ gem or Cis w/ FU adj x3 🚀endpoint: 3y PFS 👉3Y PFS: 83.9% (cis/gem) vs. 71.5% (cis/FU) HR: 0.54; p=0.023 👉Cis/gem: ⬆️ G3 or > AE

Thrilled to present our work in JAMA Oncology!! 3 molecular subtypes of colorectal liver metastases and an integrated clinical-molecular risk stratification are prognostic in a phase III trial -- presenting a novel framework to stage metastatic disease Tweetorial below 👇

Fun exploring the microscopic world! Getting the next #STEM generation started early 😊

Rad onc = #1 for professional fulfillment 🙌🏽

Great time at #ASTRO24 with Rohan Katipally!

Here it is! KEYNOTE-689 primary publication online now NEJM. It’s been an incredible journey with DAdkins Siteman Cancer Center @WUSM. All started in early 2010s / now with U.S. FDA approval and a new standard of care! Dana-Farber News Brigham and Women's Hospital Brigham and Women’s Department of Surgery